Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0U9QL
|
||||
| Former ID |
DNC000023
|
||||
| Drug Name |
[Nphe(1)]-nociceptin (1-13)-NH(2)
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C21H27F2N4O6P
|
||||
| Canonical SMILES |
CN1C=C(C(=N1)C(F)F)C(=O)NC2=CC=CC=C2C3CC3C4CC4.C(C(=O)O<br />)NCP(=O)(O)O
|
||||
| InChI |
1S/C18H19F2N3O.C3H8NO5P/c1-23-9-14(16(22-23)17(19)20)18(24)21-15-5-3-2-4-11(15)13-8-12(13)10-6-7-10;5-3(6)1-4-2-10(7,8)9/h2-5,9-10,12-13,17H,6-8H2,1H3,(H,21,24);4H,1-2H2,(H,5,6)(H2,7,8,9)
|
||||
| InChIKey |
ZLEQCJLOZSQAHT-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 1071-83-6
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| ChEBI ID |
ChEBI:27744
|
||||
| Target and Pathway | |||||
| Target(s) | Nociceptin receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1695). | ||||
| REF 2 | Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test. Naunyn Schmiedebergs Arch Pharmacol. 2002 Feb;365(2):164-7. Epub 2001 Dec 20. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.